Rise of the planet of rare anemias: An update on emerging treatment strategies

被引:8
作者
Fattizzo, Bruno [1 ,2 ]
Motta, Irene [3 ,4 ]
机构
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, SC Ematol, Milan, Italy
[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, SC Med Indirizzo Metab, Milan, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
关键词
beta-thalassemia; sickle cell disease; congenital hemolytic anemias; pyruvate kinase deficiency; autoimmune hemolytic anemia; cold agglutinin disease; paroxysmal nocturnal hemoglobinuria; aplastic anemia; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PHASE-3; TRIAL; ELTROMBOPAG; IMMUNOSUPPRESSION; ECULIZUMAB; INHIBITOR; MITAPIVAT;
D O I
10.3389/fmed.2022.1097426
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Therapeutic options for rare congenital (hemoglobinopathies, membrane and enzyme defects, congenital dyserythropoietic anemia) and acquired anemias [warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease CAD, paroxysmal nocturnal hemoglobinuria (PNH), and aplastic anemia (AA)] are rapidly expanding. The use of luspatercept, mitapivat and etavopivat in beta-thalassemia and pyruvate kinase deficiency (PKD) improves transfusion dependence, alleviating iron overload and long-term complications. Voxelotor, mitapivat, and etavopivat reduce vaso-occlusive crises in sickle cell disease (SCD). Gene therapy represents a fascinating approach, although patient selection, the toxicity of the conditioning regimens, and the possible long-term safety are still open issues. For acquired forms, wAIHA and CAD will soon benefit from targeted therapies beyond rituximab, including B-cell/plasma cell targeting agents (parsaclisib, rilzabrutinib, and isatuximab for wAIHA), complement inhibitors (pegcetacoplan and sutimlimab for CAD, ANX005 for wAIHA with complement activation), and inhibitors of extravascular hemolysis in the reticuloendothelial system (fostamatinib and FcRn inhibitors in wAIHA). PNH treatment is moving from the intravenous anti-C5 eculizumab to its long-term analog ravulizumab, and to subcutaneous and oral proximal inhibitors (anti-C3 pegcetacoplan, factor D and factor B inhibitors danicopan and iptacopan). These drugs have the potential to improve patient convenience and ameliorate residual anemia, although patient compliance becomes pivotal, and long-term safety requires further investigation. Finally, the addition of eltrombopag significantly ameliorated AA outcomes, and data regarding the alternative agent romiplostim are emerging. The accelerated evolution of treatment strategies will need further effort to identify the best candidate for each treatment in the precision medicine era.
引用
收藏
页数:11
相关论文
共 68 条
  • [21] Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria
    Fattizzo, Bruno
    Kulasekararaj, Austin G.
    [J]. BIODRUGS, 2020, 34 (02) : 149 - 158
  • [22] Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation
    Fattizzo, Bruno
    Levati, Giorgia
    Cassin, Ramona
    Barcellini, Wilma
    [J]. DRUGS, 2019, 79 (12) : 1305 - 1319
  • [23] CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
    Frangoul, H.
    Altshuler, D.
    Cappellini, M. D.
    Chen, Y-S
    Domm, J.
    Eustace, B. K.
    Foell, J.
    de la Fuente, J.
    Grupp, S.
    Handgretinger, R.
    Ho, T. W.
    Kattamis, A.
    Kernytsky, A.
    Lekstrom-Himes, J.
    Li, A. M.
    Locatelli, F.
    Mapara, M. Y.
    de Montalembert, M.
    Rondelli, D.
    Sharma, A.
    Sheth, S.
    Soni, S.
    Steinberg, M. H.
    Wall, D.
    Yen, A.
    Corbacioglu, S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (03) : 252 - 260
  • [24] Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond
    Gavriilaki, Eleni
    de latour, Egis Peffault
    Risitano, Antonio Maria
    [J]. BLOOD, 2022, 139 (25) : 3571 - 3582
  • [25] Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial
    Glenthoj, Andreas
    van Beers, Eduard J.
    Al-Samkari, Hanny
    Viprakasit, Vip
    Kuo, Kevin H. M.
    Galacteros, Frederic
    Chonat, Satheesh
    Porter, John
    Zagadailov, Erin
    Xu, Rengyi
    Oluyadi, Abdulafeez
    Hawkins, Peter
    Gheuens, Sarah
    Beynon, Vanessa
    Barcellini, Wilma
    [J]. LANCET HAEMATOLOGY, 2022, 9 (10): : E724 - E732
  • [26] Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease
    Goyal, Sunita
    Tisdale, John
    Schmidt, Manfred
    Kanter, Julie
    Jaroscak, Jennifer
    Whitney, Dustin
    Bitter, Hans
    Gregory, Philip D.
    Parsons, Geoffrey
    Foos, Marianna
    Yeri, Ashish
    Gioia, Maple
    Voytek, Sarah B.
    Miller, Alex
    Lynch, Jessie
    Colvin, Richard A.
    Bonner, Melissa
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (02) : 138 - 147
  • [27] Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
    Grace, Rachael F.
    Rose, Christian
    Layton, D. Mark
    Galacteros, Frederic
    Barcellini, Wilma
    Morton, D. Holmes
    van Beers, Eduard J.
    Yaish, Hassan
    Ravindranath, Yaddanapudi
    Kuo, Kevin H. M.
    Sheth, Sujit
    Kwiatkowski, Janet L.
    Barbier, Ann J.
    Bodie, Susan
    Silver, Bruce
    Hua, Lei
    Kung, Charles
    Hawkins, Peter
    Jouvin, Marie-Helene
    Bowden, Chris
    Glader, Bertil
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (10) : 933 - 944
  • [28] Grace RF., 2022, HEMASPHERE, V6, P1428, DOI [10.1097/01.HS9.0000849044.32404.85, DOI 10.1097/01.HS9.0000849044.32404.85]
  • [29] Grace RF., 2022, HEMASPHERE, V6, P1426, DOI [10.1097/01.HS9.0000849036.11558.e5, DOI 10.1097/01.HS9.0000849036.11558.E5]
  • [30] Grace RF., 2022, HEMASPHERE, V6, P1427, DOI [10.1097/01.HS9.0000849040.78582.c7, DOI 10.1097/01.HS9.0000849040.78582.C7]